NEW YORK / RankWire.AI / – U.S. equities closed higher on Wednesday, supported by a notable decline in long-term Treasury yields, which helped boost investor sentiment on Wall Street. The S&P 500 increased by 16.22 points, or 0.21%, finishing at 7,707.98. The Dow Jones Industrial Average gained 119.65 points, or 0.22%, ending the session at 53,463.05. Meanwhile, the Nasdaq Composite moved up by 41.38 points, or 0.16%, closing at 26,331.09. These gains marked the end of a three-day losing streak for all three principal U.S. indexes.
Much of the market movement was influenced by the bond market after the U.S. Treasury Department announced plans for increased liquidity support through buybacks of longer-dated debt. Starting from September 9, the maximum purchase amount will be raised to at least $4 billion per operation from the previous $2 billion, applying to nominal coupon securities within the 10-to-20-year and 20-to-30-year maturity ranges. The department indicated that these larger purchases will continue until November 4 and are in response to strong volumes of high-quality offers.
Following this announcement, Treasury yields declined as bond prices climbed, with the benchmark 10-year yield dropping to around 4.65%, and the 30-year yield falling to approximately 5.20%. The 30-year rate had climbed to 5.337% on Tuesday, reaching its highest point since 2007. The decrease in yields alleviated some of the pressure higher borrowing costs had exerted on equities, contributing to Wall Street’s recovery from earlier weekly losses.
Healthcare stocks buoy the market amid positive trial results
Shares in the healthcare sector gained ground following Moderna and Merck’s release of encouraging late-stage trial data from a melanoma study. Moderna’s stock surged by 177%, while Merck’s shares increased by 12.6% during the trading session. Their Phase 3 INTerpath-001 trial evaluated the combination of intismeran autogene with Keytruda after surgical procedures for patients with high-risk melanoma. The trial successfully met its primary endpoint, which measured recurrence-free survival, and also achieved a key secondary endpoint indicating survival without the spread of cancer to distant parts of the body.
Consumer stocks also experienced gains as several large corporations reported quarterly earnings, with Estée Lauder rising more than 16% following its earnings report. Additionally, Target and Lowe’s saw their shares increase after releasing their latest financial results. Smaller-cap stocks outperformed the major large-cap indexes, with the Russell 2000 climbing approximately 0.5%, broadening the market’s recovery beyond the healthcare sector. Technology stocks showed mixed performance, limiting the extent of gains across major indices.
Week-to-date declines persist despite Wednesday’s rebound
Even with Wednesday’s positive movement, the three key U.S. stock indexes remained lower for the week ending at close, with the S&P 500 approximately 1% below its level from the previous Friday. The Dow was roughly 0.5% lower, and the Nasdaq had declined about 1.5%. The market rebound was driven by a retreat in long-term yields, which had previously weighed heavily on stock valuations and led investors to adopt a more cautious approach across various sectors of equities.
As of Wednesday’s close, the major averages stayed firmly in positive territory for 2026, with the S&P 500 up about 12.6% since January 1. The Dow advanced roughly 11.2%, and the Nasdaq increased around 13.3%. Wednesday’s session represented a modest recovery for Wall Street, fueled by falling Treasury yields and significant gains in healthcare stocks. The market movement was mainly influenced by the U.S. Treasury Department’s buyback initiative and positive results from the melanoma trial, which stood out as the clearest drivers during the trading day.